Christophe Marguet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Christophe Marguet has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Hortense Petat
Department of Pediatrics and Adolescent Medicine, Pulmonology, Allergy and CF UnivRouen Normandie, UMR 1311, DYNAMICURE, FHU Respire, CHU Rouen Rouen France
3 shared publications Laure Couderc
Paediatric Department CHU Charles Nicolle Rouen France
2 shared publications- Alexia Letierce
QualityStat, Morangis, France
1 shared publication - Alfonso Galderisi
Department of Pediatrics, Yale University, New Haven, USA
1 shared publication - Alice Michel
Univ Rouen Normandie, Université de Caen Normandie, INSERM, Normandie Univ, DYNAMICURE UMR 1311 Rouen France
1 shared publication Aline Lustre
Hôpital Universitaire Necker-Enfants Malades–APHP, Centre de Références Maladies Rares, Mucoviscidose et Maladies apparentée , 75015 Paris
1 shared publication
Latest Publications
- Open Access
- 17 August 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (8) , e70449
Bronchoalveolar cytokine profiling identifies distinct endotypes in severe recurrent wheeze of infancy
- 17 August 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (8) , e70449
Open AccessBronchoalveolar cytokine profiling identifies distinct endotypes in severe recurrent wheeze of infancy
- Open Access
- 1 January 2026
- Published by Wiley in Canadian Respiratory Journal
- Vol. 2026 (1) , 9033903
How Should IgG Seroconversion to Aspergillus fumigatus be Interpreted in Children With Cystic Fibrosis
Background: Cystic fibrosis (CF) is one of the most common autosomal recessive diseases in the world population. Allergic bronchopulmonary aspergillosis (ABPA) is a severe complication of CF, the diagnosis of which is based on symptoms and blood IgE levels. However, many techniques of specific IgG levels’ measures are used, whose clinical significance is still unclear. We evaluated the clinical evolution of CF in children who presented a first A. fumigatus IgG seroconversion. Methods: Monocentric pediatric case‐control study led in Rouen, France. Every patient with a first A. fumigatus IgG seroconversion was paired with a seronegative patient. Clinical data, functional respiratory investigations, CT scan, and biologic data were collected a year before ( Y −1 ), at the time of IgG seroconversion ( Y 0 ), and one year after ( Y +1 ). Results: Thirty‐six cases were paired with 36 controls. Median age was 8. Forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) were significantly lower at Y +1 ( p = 0.025) and Y 0 ( p = 0.027), respectively, and more pulmonary exacerbations were observed in the case population ( p = 0.047). Higher levels of specific IgE against A. fumigatus were observed at Y −1 ( p = 0.001), Y 0 ( p = 0.014), and Y +1 ( p = 0.04) in the case population. On the CT scan, bronchiectasis and pulmonary infiltrates were more frequent in the case population ( p = 0.01 and p = 0.003, respectively). Conclusion: We found that the first A. fumigatus IgG seroconversion was associated with changes in clinical, respiratory functional, biologic, and radiologic parameters in CF pediatric population. A. fumigatus IgG seroconversion is an important step in the evolution of CF. A systematic search for seroconversion is therefore essential to assess the measures to be taken.
- 1 January 2026
- Published by Wiley in Canadian Respiratory Journal
- Vol. 2026 (1) , 9033903
Open AccessHow Should IgG Seroconversion to Aspergillus fumigatus be Interpreted in Children With Cystic Fibrosis
Background: Cystic fibrosis (CF) is one of the most common autosomal recessive diseases in the world population. Allergic bronchopulmonary aspergillosis (ABPA) is a severe complication of CF, the diagnosis of which is based on symptoms and blood IgE levels. However, many techniques of specific IgG levels’ measures are used, whose clinical significance is still unclear. We evaluated the clinical evolution of CF in children who presented a first A. fumigatus IgG seroconversion. Methods: Monocentric pediatric case‐control study led in Rouen, France. Every patient with a first A. fumigatus IgG seroconversion was paired with a seronegative patient. Clinical data, functional respiratory investigations, CT scan, and biologic data were collected a year before ( Y −1 ), at the time of IgG seroconversion ( Y 0 ), and one year after ( Y +1 ). Results: Thirty‐six cases were paired with 36 controls. Median age was 8. Forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) were significantly lower at Y +1 ( p = 0.025) and Y 0 ( p = 0.027), respectively, and more pulmonary exacerbations were observed in the case population ( p = 0.047). Higher levels of specific IgE against A. fumigatus were observed at Y −1 ( p = 0.001), Y 0 ( p = 0.014), and Y +1 ( p = 0.04) in the case population. On the CT scan, bronchiectasis and pulmonary infiltrates were more frequent in the case population ( p = 0.01 and p = 0.003, respectively). Conclusion: We found that the first A. fumigatus IgG seroconversion was associated with changes in clinical, respiratory functional, biologic, and radiologic parameters in CF pediatric population. A. fumigatus IgG seroconversion is an important step in the evolution of CF. A systematic search for seroconversion is therefore essential to assess the measures to be taken.
- 20 February 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Adolescents With Cystic Fibrosis
Context: Highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators, such as elexacaftor/tezacaftor/ivacaftor (ETI), herald a new era in therapeutic strategy of cystic fibrosis (CF). ETI’s effect on glucose tolerance remains controversial. Objective: The study was undertaken to evaluate the effect of ETI treatment on glucose tolerance in youths with CF. Methods: All the participants underwent a baseline oral glucose tolerance test (OGTT) before ETI initiation (M0) and 12 months (M12), and at 24 months if possible. The cohort was stratified in two subgroups based on the baseline OGTT: normal glucose tolerance (NGT) and abnormal glucose tolerance (AGT) defined by impaired fasting glucose or impaired glucose tolerance or diabetes not requiring insulin treatment. Results: We included 106 adolescents with CF (age 14.1 ± 1.5 years), 75 with NGT, and 31 with AGT. The baseline characteristics of the two groups were similar except for a higher glucose level at 1- and 2-hour OGTT in the AGT group. ETI induced an increase in body mass index z score and in forced expiratory volume in 1 second (FEV1) (P < .001). After 12 months, participants with NGT did not experience any change of 1-hour and 2-hour glucose. By contrast, those with AGT displayed a reduction of 2-hour glucose at M12 (P = .006). Fifteen out of the 31 (48%) adolescents in the AGT group reversed to NGT but 9 of 75 (17%) in the NGT group progressed to AGT. Three participants with CF-related diabetes at baseline reversed to AGT. One-hour glucose concentrations at or above 8.7 mmol/L (157 mg/dL) during baseline OGTT had 80% sensitivity to identify those with AGT at 12 months (odds ratio 1.51; [1.20-1.92]; P = .001). Twenty participants had a 24-month OGTT that confirmed preserved insulin secretion. Conclusion: ETI may improve glucose tolerance in adolescents with CF by preserving insulin secretion. One-hour glucose during the OGTT helps to detect risk for AGT after ETI treatment.
- 20 February 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Adolescents With Cystic Fibrosis
Context: Highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators, such as elexacaftor/tezacaftor/ivacaftor (ETI), herald a new era in therapeutic strategy of cystic fibrosis (CF). ETI’s effect on glucose tolerance remains controversial. Objective: The study was undertaken to evaluate the effect of ETI treatment on glucose tolerance in youths with CF. Methods: All the participants underwent a baseline oral glucose tolerance test (OGTT) before ETI initiation (M0) and 12 months (M12), and at 24 months if possible. The cohort was stratified in two subgroups based on the baseline OGTT: normal glucose tolerance (NGT) and abnormal glucose tolerance (AGT) defined by impaired fasting glucose or impaired glucose tolerance or diabetes not requiring insulin treatment. Results: We included 106 adolescents with CF (age 14.1 ± 1.5 years), 75 with NGT, and 31 with AGT. The baseline characteristics of the two groups were similar except for a higher glucose level at 1- and 2-hour OGTT in the AGT group. ETI induced an increase in body mass index z score and in forced expiratory volume in 1 second (FEV1) (P < .001). After 12 months, participants with NGT did not experience any change of 1-hour and 2-hour glucose. By contrast, those with AGT displayed a reduction of 2-hour glucose at M12 (P = .006). Fifteen out of the 31 (48%) adolescents in the AGT group reversed to NGT but 9 of 75 (17%) in the NGT group progressed to AGT. Three participants with CF-related diabetes at baseline reversed to AGT. One-hour glucose concentrations at or above 8.7 mmol/L (157 mg/dL) during baseline OGTT had 80% sensitivity to identify those with AGT at 12 months (odds ratio 1.51; [1.20-1.92]; P = .001). Twenty participants had a 24-month OGTT that confirmed preserved insulin secretion. Conclusion: ETI may improve glucose tolerance in adolescents with CF by preserving insulin secretion. One-hour glucose during the OGTT helps to detect risk for AGT after ETI treatment.
- Open Access
- 24 November 2023
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 11, 1269805
Positive and negative viral associations in patients with acute respiratory tract infections in primary care: the ECOVIR study
Introduction: Acute respiratory infections (ARIs) are the most common viral infections encountered in primary care settings. The identification of causal viruses is still not available in routine practice. Although new strategies of prevention are being identified, knowledge of the relationships between respiratory viruses remains limited.Materials and methods: ECOVIR was a multicentric prospective study in primary care, which took place during two pre-pandemic seasons (2018–2019 and 2019–2020). Patients presenting to their General practitioner (GP) with ARIs were included, without selecting for age or clinical conditions. Viruses were detected on nasal swab samples using a multiplex Polymerase Chain Reaction test focused on 17 viruses [Respiratory Syncytial Virus-A (RSV-A), RSV-B, Rhinovirus/Enterovirus (HRV), human Metapneumovirus (hMPV), Adenovirus (ADV), Coronaviruses (CoV) HKU1, NL63, 229E, OC43, Influenza virus (H1 and H3 subtypes), Influenza virus B, Para-Influenza viruses (PIVs) 1–4, and Bocavirus (BoV)].Results: Among the 668 analyzed samples, 66% were positive for at least one virus, of which 7.9% were viral codetections. The viral detection was negatively associated with the age of patients. BoV, ADV, and HRV occurred more significantly in younger patients than the other viruses (p < 0.05). Codetections were significantly associated with RSV, HRV, BoV, hMPV, and ADV and not associated with influenza viruses, CoV, and PIVs. HRV and influenza viruses were negatively associated with all the viruses. Conversely, a positive association was found between ADV and BoV and between PIVs and BoV.Conclusion: Our study provides additional information on the relationships between respiratory viruses, which remains limited in primary care.
- 24 November 2023
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 11, 1269805
Open AccessPositive and negative viral associations in patients with acute respiratory tract infections in primary care: the ECOVIR study
Introduction: Acute respiratory infections (ARIs) are the most common viral infections encountered in primary care settings. The identification of causal viruses is still not available in routine practice. Although new strategies of prevention are being identified, knowledge of the relationships between respiratory viruses remains limited.Materials and methods: ECOVIR was a multicentric prospective study in primary care, which took place during two pre-pandemic seasons (2018–2019 and 2019–2020). Patients presenting to their General practitioner (GP) with ARIs were included, without selecting for age or clinical conditions. Viruses were detected on nasal swab samples using a multiplex Polymerase Chain Reaction test focused on 17 viruses [Respiratory Syncytial Virus-A (RSV-A), RSV-B, Rhinovirus/Enterovirus (HRV), human Metapneumovirus (hMPV), Adenovirus (ADV), Coronaviruses (CoV) HKU1, NL63, 229E, OC43, Influenza virus (H1 and H3 subtypes), Influenza virus B, Para-Influenza viruses (PIVs) 1–4, and Bocavirus (BoV)].Results: Among the 668 analyzed samples, 66% were positive for at least one virus, of which 7.9% were viral codetections. The viral detection was negatively associated with the age of patients. BoV, ADV, and HRV occurred more significantly in younger patients than the other viruses (p < 0.05). Codetections were significantly associated with RSV, HRV, BoV, hMPV, and ADV and not associated with influenza viruses, CoV, and PIVs. HRV and influenza viruses were negatively associated with all the viruses. Conversely, a positive association was found between ADV and BoV and between PIVs and BoV.Conclusion: Our study provides additional information on the relationships between respiratory viruses, which remains limited in primary care.